343 related articles for article (PubMed ID: 18362173)
21. Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers.
Jeong EG; Kim MS; Nam HK; Min CK; Lee S; Chung YJ; Yoo NJ; Lee SH
Clin Cancer Res; 2008 Jun; 14(12):3716-21. PubMed ID: 18559588
[TBL] [Abstract][Full Text] [Related]
22. Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia.
Malinge S; Ben-Abdelali R; Settegrana C; Radford-Weiss I; Debre M; Beldjord K; Macintyre EA; Villeval JL; Vainchenker W; Berger R; Bernard OA; Delabesse E; Penard-Lacronique V
Blood; 2007 Mar; 109(5):2202-4. PubMed ID: 17068151
[TBL] [Abstract][Full Text] [Related]
23. Interleukin-7 signaling in human B cell precursor acute lymphoblastic leukemia cells and murine BAF3 cells involves activation of STAT1 and STAT5 mediated via the interleukin-7 receptor alpha chain.
van der Plas DC; Smiers F; Pouwels K; Hoefsloot LH; Löwenberg B; Touw IP
Leukemia; 1996 Aug; 10(8):1317-25. PubMed ID: 8709637
[TBL] [Abstract][Full Text] [Related]
24. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model.
Degryse S; de Bock CE; Cox L; Demeyer S; Gielen O; Mentens N; Jacobs K; Geerdens E; Gianfelici V; Hulselmans G; Fiers M; Aerts S; Meijerink JP; Tousseyn T; Cools J
Blood; 2014 Nov; 124(20):3092-100. PubMed ID: 25193870
[TBL] [Abstract][Full Text] [Related]
25. JAK1 mutation analysis in T-cell acute lymphoblastic leukemia cell lines.
Porcu M; Gielen O; Cools J; De Keersmaecker K
Haematologica; 2009 Mar; 94(3):435-7. PubMed ID: 19176360
[No Abstract] [Full Text] [Related]
26. Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia.
Kiel MJ; Velusamy T; Rolland D; Sahasrabuddhe AA; Chung F; Bailey NG; Schrader A; Li B; Li JZ; Ozel AB; Betz BL; Miranda RN; Medeiros LJ; Zhao L; Herling M; Lim MS; Elenitoba-Johnson KS
Blood; 2014 Aug; 124(9):1460-72. PubMed ID: 24825865
[TBL] [Abstract][Full Text] [Related]
27. IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study.
Li Y; Buijs-Gladdines JG; Canté-Barrett K; Stubbs AP; Vroegindeweij EM; Smits WK; van Marion R; Dinjens WN; Horstmann M; Kuiper RP; Buijsman RC; Zaman GJ; van der Spek PJ; Pieters R; Meijerink JP
PLoS Med; 2016 Dec; 13(12):e1002200. PubMed ID: 27997540
[TBL] [Abstract][Full Text] [Related]
28. Identification of mutant alleles of JAK3 in pediatric patients with acute lymphoblastic leukemia.
Yin C; Sandoval C; Baeg GH
Leuk Lymphoma; 2015 May; 56(5):1502-6. PubMed ID: 25146434
[TBL] [Abstract][Full Text] [Related]
29. Simultaneous activation of JAK1 and JAK2 confers IL-3 independent growth on Ba/F3 pro-B cells.
Huang HM; Lin YL; Chen CH; Chang TW
J Cell Biochem; 2005 Oct; 96(2):361-75. PubMed ID: 15988755
[TBL] [Abstract][Full Text] [Related]
30. Biallelic JAK1 mutations in immunodeficient patient with mycobacterial infection.
Eletto D; Burns SO; Angulo I; Plagnol V; Gilmour KC; Henriquez F; Curtis J; Gaspar M; Nowak K; Daza-Cajigal V; Kumararatne D; Doffinger R; Thrasher AJ; Nejentsev S
Nat Commun; 2016 Dec; 7():13992. PubMed ID: 28008925
[TBL] [Abstract][Full Text] [Related]
31. MOHITO, a novel mouse cytokine-dependent T-cell line, enables studies of oncogenic signaling in the T-cell context.
Kleppe M; Mentens N; Tousseyn T; Wlodarska I; Cools J
Haematologica; 2011 May; 96(5):779-83. PubMed ID: 21193420
[TBL] [Abstract][Full Text] [Related]
32. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias.
Kucine N; Marubayashi S; Bhagwat N; Papalexi E; Koppikar P; Sanchez Martin M; Dong L; Tallman MS; Paietta E; Wang K; He J; Lipson D; Stephens P; Miller V; Rowe JM; Teruya-Feldstein J; Mullighan CG; Ferrando AA; Krivtsov A; Armstrong S; Leung L; Ochiana SO; Chiosis G; Levine RL; Kleppe M
Blood; 2015 Nov; 126(22):2479-83. PubMed ID: 26443624
[TBL] [Abstract][Full Text] [Related]
33. Dual role of the Jak1 FERM and kinase domains in cytokine receptor binding and in stimulation-dependent Jak activation.
Haan S; Margue C; Engrand A; Rolvering C; Schmitz-Van de Leur H; Heinrich PC; Behrmann I; Haan C
J Immunol; 2008 Jan; 180(2):998-1007. PubMed ID: 18178840
[TBL] [Abstract][Full Text] [Related]
34. Structural modeling of JAK1 mutations in T-cell acute lymphoblastic leukemia reveals a second contact site between pseudokinase and kinase domains.
Canté-Barrett K; Uitdehaag JC; Meijerink JP
Haematologica; 2016 May; 101(5):e189-91. PubMed ID: 26819051
[No Abstract] [Full Text] [Related]
35. A single tyrosine of the interleukin-9 (IL-9) receptor is required for STAT activation, antiapoptotic activity, and growth regulation by IL-9.
Demoulin JB; Uyttenhove C; Van Roost E; DeLestré B; Donckers D; Van Snick J; Renauld JC
Mol Cell Biol; 1996 Sep; 16(9):4710-6. PubMed ID: 8756628
[TBL] [Abstract][Full Text] [Related]
36. JAK1 truncating mutations in gynecologic cancer define new role of cancer-associated protein tyrosine kinase aberrations.
Ren Y; Zhang Y; Liu RZ; Fenstermacher DA; Wright KL; Teer JK; Wu J
Sci Rep; 2013 Oct; 3():3042. PubMed ID: 24154688
[TBL] [Abstract][Full Text] [Related]
37. New strategies in acute lymphoblastic leukemia: translating advances in genomics into clinical practice.
Mullighan CG
Clin Cancer Res; 2011 Feb; 17(3):396-400. PubMed ID: 21149616
[TBL] [Abstract][Full Text] [Related]
38. Lack of constitutive activation of Janus kinases and signal transduction and activation of transcription factors in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Kanwar VS; Witthuhn B; Campana D; Ihle JN
Blood; 1996 Jun; 87(11):4911-2. PubMed ID: 8639867
[No Abstract] [Full Text] [Related]
39. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia.
Feng J; Li Y; Jia Y; Fang Q; Gong X; Dong X; Ru K; Li Q; Zhao X; Liu K; Wang M; Tian Z; Jia Y; Wang Y; Lin D; Wei H; Tang K; Mi Y; Wang J
J Hematol Oncol; 2017 Feb; 10(1):61. PubMed ID: 28245838
[TBL] [Abstract][Full Text] [Related]
40. Bone marrow-derived mesenchymal stromal cells promote resistance to tyrosine kinase inhibitors in chronic myeloid leukemia via the IL-7/JAK1/STAT5 pathway.
Zhang X; Tu H; Yang Y; Jiang X; Hu X; Luo Q; Li J
J Biol Chem; 2019 Aug; 294(32):12167-12179. PubMed ID: 31235520
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
